

Drug Monograph

Drug/Drug Class: **Aerospan™ (flunisolide) Inhaler / inhaled corticosteroid**
 Prepared for: MO HealthNet
 Prepared by: Xerox Heritage, LLC

New Criteria

Revision of Existing Criteria

Executive Summary

Purpose:	The purpose of this monograph is to provide a review of new therapy to determine whether the reviewed drug should be made available on an open access basis to prescribers, require a clinical edit or require prior authorization for use.
Dosage Forms:	Aerospan™ is available in two metered pumps containing 60 or 120 metered 80 mcg-does of flusinolide.
Manufacturer:	Manufactured By: 3M Drug Delivery Systems. Northridge, CA 91324. For: Acton Pharmaceuticals, Inc., Marlborough, MA 01752
Indications:	Aerospan™ Inhalation Aerosol is indicated for the maintenance treatment of asthma as prophylactic therapy in adult and pediatric patients 6 years of age and older.
Costs:	\$1.29166 per actuation of Aerospan™ WholesaleAcquisitionCost
Summary of Findings:	This drug is being considered for inclusion in the state specific Preferred Drug List (PDL).
Status Recommendation:	<input type="checkbox"/> Prior Authorization (PA) Required <input type="checkbox"/> Open Access <input type="checkbox"/> Fiscal Edit <input checked="" type="checkbox"/> PDL
Type of PA Criteria:	<input type="checkbox"/> Increased Risk of ADE <input checked="" type="checkbox"/> Under Solicitation <input type="checkbox"/> Appropriate Indications <input type="checkbox"/> No PA Required

Prepared By: Katie Wilbers, PharmD
 Date: February 27, 2014